STEROIDOGENESIS INHIBITORS INTERNATIONAL INC
SB-2, EX-27, 2000-12-20
BUSINESS SERVICES, NEC
Previous: STEROIDOGENESIS INHIBITORS INTERNATIONAL INC, SB-2, EX-23.2, 2000-12-20
Next: FIRST SECURITY AUTO GRANTOR TRUST 1998-A, 8-K, 2000-12-20



<TABLE> <S> <C>


<ARTICLE>                         5
<LEGEND>
</LEGEND>
<CIK>                             0001057377
<NAME>                            Steroidogenesis Inhibitors International, Inc.
<MULTIPLIER>                                                          1,000
<CURRENCY>                                                       US DOLLARS

<S>                               <C>             <C>           <C>
<PERIOD-TYPE>                     YEAR           YEAR           9-MOS
<FISCAL-YEAR-END>                 DEC-31-1998    DEC-31-1999    DEC-31-2000
<PERIOD-START>                    JAN-01-1998    JAN-01-1999    JAN-01-2000
<PERIOD-END>                      DEC-31-1998    DEC-31-1999    SEP-30-2000
<EXCHANGE-RATE>                             1              1              1
<CASH>                                      0              2             33
<SECURITIES>                                0              0              0
<RECEIVABLES>                              13             11             17
<ALLOWANCES>                                0              0              0
<INVENTORY>                                 0              0              0
<CURRENT-ASSETS>                           14             13             50
<PP&E>                                     29             47             47
<DEPRECIATION>                            (11)           (17)            23
<TOTAL-ASSETS>                            175            202            242
<CURRENT-LIABILITIES>                      99            465            946
<BONDS>                                     0              0              0
                       0              0              0
                                 0              0              0
<COMMON>                                3,969          5,300         11,428
<OTHER-SE>                             (4,142)        (5,814)       (12,383)
<TOTAL-LIABILITY-AND-EQUITY>             (174)          (514)          (955)
<SALES>                                     0              0              0
<TOTAL-REVENUES>                            0             50              0
<CGS>                                       0              0              0
<TOTAL-COSTS>                           1,010          1,721          6,569
<OTHER-EXPENSES>                            0              0              0
<LOSS-PROVISION>                            0              0              0
<INTEREST-EXPENSE>                          0             14              2
<INCOME-PRETAX>                        (1,010)        (1,671)        (6,569)
<INCOME-TAX>                           (1,010)        (1,671)        (6,569)
<INCOME-CONTINUING>                    (1,010)        (1,671)        (6,569)
<DISCONTINUED>                              0              0              0
<EXTRAORDINARY>                             0              0              0
<CHANGES>                                   0              0              0
<NET-INCOME>                           (1,010)        (1,671)        (6,569)
<EPS-BASIC>                             (0.11)         (0.12)         (0.38)
<EPS-DILUTED>                           (0.11)         (0.12)         (0.38)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission